Street Calls of the Week
Investing.com - Piper Sandler has reiterated an Overweight rating and $26.00 price target on Inventiva SA (NASDAQ:IVA), maintaining a positive outlook on the company’s prospects in the MASH (metabolic dysfunction-associated steatohepatitis) therapeutic space. The stock has shown remarkable strength with a 221% return over the past year, according to InvestingPro data.
The firm expressed confidence in the high probability of success for lanifibranor, Inventiva’s oral pan-PPAR agonist, in its Phase 3 NATiV3 trial with topline results expected in the second half of 2026.
Piper Sandler highlighted Novo Nordisk’s recent acquisition of Akero Therapeutics as evidence of growing strategic interest in novel MASH therapeutics, particularly those that complement large pharmaceutical companies’ existing metabolic pipelines.
The research firm emphasized lanifibranor’s product profile, noting its potential to deliver both intrahepatic and extrahepatic benefits in MASH patients while maintaining a strong safety and tolerability profile.
Piper Sandler characterized the current timing as favorable for investment in Inventiva, describing the upcoming Phase 3 NATiV3 readout as "significantly de-risked" and supporting their bullish stance on the stock.
In other recent news, Inventiva has seen a series of analyst updates highlighting its drug candidate lanifibranor, which is being developed for metabolic dysfunction-associated steatohepatitis (MASH). H.C. Wainwright raised its price target for Inventiva to $24 from $20, maintaining a Buy rating, emphasizing lanifibranor’s unique position as the only oral, once-daily pan PPAR agonist in late-stage development. Stifel also reiterated its Buy rating with a $17 price target, citing lanifibranor’s best-in-class profile and multi-targeted approach to MASH and liver fibrosis. Meanwhile, Guggenheim increased its price target to $13 from $9, driven by growing enthusiasm for the MASH market and the target patient population. Piper Sandler initiated coverage with an Overweight rating and a $26 price target, noting the potential of lanifibranor and the expected Phase 3 NATiV3 topline results in the second half of 2026. Additionally, H.C. Wainwright assumed coverage with a Buy rating and a $20 price target, referencing the FDA’s acceptance of a letter of intent for liver stiffness measurement as a surrogate endpoint. These developments reflect a positive outlook among analysts for Inventiva’s ongoing efforts in drug development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.